The group of Florian Grebien at the Institute for Medical Biochemistry at the University of Veterinary Medicine Vienna is looking for a motivated and experienced individual to work on
Genetic determinants of drug response and resistance in leukemia
The genetic heterogeneity of leukemia poses a significant challenge for the establishment of treatment options in a personalized fashion. While a large number of targeted treatment options are currently being tested for their clinical benefit, little is known about cellular factors that mediate response and resistance to these drugs. In addition, biomarkers that can reliably identify responsive patient groups are often lacking.
In this project we aim to use CRISPR/Cas9-mediated screening to obtain a better mechanistic understanding of how specific gene expression patterns influence the sensitivity of leukemia cells to approved and experimental therapeutic options. The project will involve experimental work using leukemia cell lines, mouse models and primary patient material as well as bioinformatic analysis and integration of datasets that are publicly available or were generated in-house.
The group of Florian Grebien is using a multidisciplinary approach consisting of proteomics, genomics and CRISPR/Cas9-mediated genome engineering in advanced cell line- and mouse models of cancer. By combining wet-lab- and bioinformatics approaches we constantly gain novel insights in the molecular basis of molecular mechanisms of leukemogenesis (e.g. see https://doi.org/10.1038/s41467-018-04329-y, https://doi.org/10.1182/blood.2019003267 and https://doi.org/10.1038/s41594-020-00550-w)
Our laboratory is embedded in the existing infrastructure of the Department for Biomedical Sciences at the University of Veterinary Medicine Vienna. The wider network of the group is constituted by several close national and international collaborations.
We are looking for a motivated researcher who holds a PhD (DVM, MD or equivalent) degree and has an excellent track record in biochemistry, cellular and molecular biology and cancer research, as documented by relevant publications in the field. Previous experience with CRISPR/Cas9 screening is a plus. The successful candidate is an individual thinker who is ambitious and self-driven. Excellent organizational skills and written and oral communication skills in English are required. If you are a curious, flexible and social person who is interested to work in an interdisciplinary team you should look into this opportunity.
Please submit a letter of motivation, a detailed Curriculum Vitae including a publication list as well as reference letters and contact details of three suggested referees to Florian Grebien (firstname.lastname@example.org) The earliest possible starting date is May 1st, 2022.
Applications are accepted until the position is filled.